Comera Life Sciences Holdings logo

Comera Life Sciences HoldingsNASDAQ: CMRA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 December 2020

Website:

http://comeralifesciences.com

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A

Market cap

$768.45 K
-99%vs. 3y high
2%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

-0.18
-20%vs. 3y high
14%vs. sector

PS ratio

0.77
-99%vs. 3y high
19%vs. sector

Price

regular market | Thu, 27 Jun 2024 13:30:00 GMT
$0.03-$0.00(-0.40%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.10-

Revenue

Revenue target

$136.30 K-

Revenue

Net income

$136.30 K-$2.15 M

Analysts recommendations

Total assets

Total liabilities

$3.07 M$7.29 M

Institutional Ownership

Included in screeners

Small cap companies
Stocks under 1$
Stocks with price below SMA 200
Stocks with low beta
Growing shares outstanding

Similar companies

Lucy Scientific Discovery logo

Lucy Scientific Discovery (LSDI)

Bellerophon Therapeutics logo

Bellerophon Therapeutics (BLPH)

Better Therapeutics logo

Better Therapeutics (BTTX)

Neptune Wellness Solutions logo

Neptune Wellness Solutions (NEPT)

China SXT Pharmaceuticals logo

China SXT Pharmaceuticals (SXTC)

CNS Pharmaceuticals logo

CNS Pharmaceuticals (CNSP)

Qualigen Therapeutics logo

Qualigen Therapeutics (QLGN)

Dermata Therapeutics logo

Dermata Therapeutics (DRMA)

CMRA Latest News

These Are the ONLY 7 Penny Stocks to Consider in August 2023
InvestorPlace26 August 2023 Sentiment: POSITIVE

Some of the most promising penny stocks can have multi-bagger potential over the long haul. After all, the combination of low prices, strong catalysts, and potentially high returns can be appealing.

What type of business is Comera Life Sciences Holdings?

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

What sector is Comera Life Sciences Holdings in?

Comera Life Sciences Holdings is in the Healthcare sector

What industry is Comera Life Sciences Holdings in?

Comera Life Sciences Holdings is in the Biotechnology industry

What country is Comera Life Sciences Holdings from?

Comera Life Sciences Holdings is headquartered in United States

When did Comera Life Sciences Holdings go public?

Comera Life Sciences Holdings initial public offering (IPO) was on 21 December 2020

What is Comera Life Sciences Holdings website?

https://comeralifesciences.com

Is Comera Life Sciences Holdings in the S&P 500?

No, Comera Life Sciences Holdings is not included in the S&P 500 index

Is Comera Life Sciences Holdings in the NASDAQ 100?

No, Comera Life Sciences Holdings is not included in the NASDAQ 100 index

Is Comera Life Sciences Holdings in the Dow Jones?

No, Comera Life Sciences Holdings is not included in the Dow Jones index

When does Comera Life Sciences Holdings report earnings?

Next earnings report date is not announced yet